Mepivacaína B. Braun

Mepivacaine, the active ingredient in Mepivacaína B. Braun, is a local anesthetic presented as a sterile solution for epidural, perineural and retrobulbar use. It provides short‑term loss of sensation for surgical and diagnostic procedures in adult patients. GNH USA supplies Mepivacaína B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Mepivacaine is a local anesthetic used in various regional anesthesia techniques to block nerve transmission. - Epidural analgesia: provides pain relief during labor, obstetric or abdominal surgery. - Perineural nerve block: creates localized anesthesia for limb or peripheral nerve surgeries. - Retrobulbar block: anesthetizes the eye for ophthalmic procedures. - Local anesthesia for surgical procedures: enables short‑term loss of sensation during minor surgeries.

Mepivacaine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Pain or irritation at the injection site - Mild dizziness or light‑headedness - Nausea or vomiting - Metallic taste in the mouth - Transient blurred vision - Temporary hypotension

Serious or Rare Side Effects: - Allergic reaction including anaphylaxis - Cardiac arrhythmias or conduction disturbances - Central nervous system toxicity such as seizures - Prolonged or unexpected numbness - Severe hypotension or cardiovascular collapse - Respiratory depression

When using mepivacaine, clinicians should observe several safety measures. - Allergy assessment: verify no known hypersensitivity to amide‑type local anesthetics. - Cardiac caution: use reduced doses in patients with pre‑existing heart disease. - Elderly patients: consider lower initial doses due to altered pharmacokinetics. - Hemodynamic monitoring: observe blood pressure and heart rate during and after injection. - Storage at ambient temperature: keep in original container, protect from light and moisture.

Mepivacaine can interact with other medicines, altering its safety profile.

Major Interactions (Avoid): - Class I antiarrhythmic agents (e.g., quinidine, procainamide): increase risk of cardiotoxicity. - Monoamine oxidase inhibitors (MAOIs): may enhance hypotensive effects.

Moderate Interactions (Monitor Closely): - Nonsteroidal anti‑inflammatory drugs (NSAIDs): may increase bleeding tendency. - Opioid analgesics: additive central nervous system depression. - Beta‑adrenergic antagonists: may mask early signs of local anesthetic toxicity.